Literature DB >> 17626889

High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition.

Irina G Obrosova1, Olga Ilnytska, Valeriy V Lyzogubov, Ivan A Pavlov, Nazar Mashtalir, Jerry L Nadler, Viktor R Drel.   

Abstract

OBJECTIVE: Subjects with dietary obesity and pre-diabetes have an increased risk for developing both nerve conduction slowing and small sensory fiber neuropathy. Animal models of this type of neuropathy have not been described. This study evaluated neuropathic changes and their amenability to dietary and pharmacological interventions in mice fed a high-fat diet (HFD), a model of pre-diabetes and alimentary obesity. RESEARCH DESIGN AND METHODS: Female C57BL6/J mice were fed normal diets or HFDs for 16 weeks.
RESULTS: HFD-fed mice developed obesity, increased plasma FFA and insulin concentrations, and impaired glucose tolerance. They also had motor and sensory nerve conduction deficits, tactile allodynia, and thermal hypoalgesia in the absence of intraepidermal nerve fiber loss or axonal atrophy. Despite the absence of overt hyperglycemia, the mice displayed augmented sorbitol pathway activity in the peripheral nerve, as well as 4-hydroxynonenal adduct nitrotyrosine and poly(ADP-ribose) accumulation and 12/15-lipoxygenase overexpression in peripheral nerve and dorsal root ganglion neurons. A 6-week feeding with normal chow after 16 weeks on HFD alleviated tactile allodynia and essentially corrected thermal hypoalgesia and sensory nerve conduction deficit without affecting motor nerve conduction slowing. Normal chow containing the aldose reductase inhibitor fidarestat (16 mg x kg(-1) x day (-1)) corrected all functional changes of HFD-induced neuropathy.
CONCLUSIONS: Similar to human subjects with pre-diabetes and obesity, HFD-fed mice develop peripheral nerve functional, but not structural, abnormalities and, therefore, are a suitable model for evaluating dietary and pharmacological approaches to halt progression and reverse diabetic neuropathy at the earliest stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626889     DOI: 10.2337/db06-1176

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  123 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

Review 2.  Functional and pathological roles of the 12- and 15-lipoxygenases.

Authors:  Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

3.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Mitochondrial stress and the pathogenesis of diabetic neuropathy.

Authors:  Paul Fernyhough; Subir K Roy Chowdhury; Robert E Schmidt
Journal:  Expert Rev Endocrinol Metab       Date:  2010-01-01

5.  Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction.

Authors:  Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 6.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

7.  High Dietary Fat Consumption Impairs Axonal Mitochondrial Function In Vivo.

Authors:  Marija Sajic; Amy E Rumora; Anish A Kanhai; Giacomo Dentoni; Sharlini Varatharajah; Caroline Casey; Ryan D R Brown; Fabian Peters; Lucy M Hinder; Masha G Savelieff; Eva L Feldman; Kenneth J Smith
Journal:  J Neurosci       Date:  2021-03-30       Impact factor: 6.167

Review 8.  A review of rodent models of type 2 diabetic skeletal fragility.

Authors:  Roberto J Fajardo; Lamya Karim; Virginia I Calley; Mary L Bouxsein
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

Review 9.  The Potential Role of Fatty Acids in Treating Diabetic Neuropathy.

Authors:  Mark A Yorek
Journal:  Curr Diab Rep       Date:  2018-08-25       Impact factor: 4.810

Review 10.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.